Aflatoxin-related hepatocellular carcinoma (HCC) is a form of liver cancer strongly associated with dietary exposure to aflatoxin B1 (AFB1), a mycotoxin produced by Aspergillus fungi that contaminate stored grains and nuts in tropical regions. Aflatoxin exposure synergizes dramatically with chronic hepatitis B virus (HBV) infection, increasing HCC risk approximately 60-fold compared to either factor alone. The molecular signature of aflatoxin-related HCC is the TP53 R249S mutation, resulting from AFB1-DNA adduct formation at codon 249. This disease exemplifies gene-environment interaction in cancer etiology and is most prevalent in sub-Saharan Africa and Southeast Asia where both aflatoxin exposure and HBV infection are endemic.
Ask a research question about Aflatoxin-Related Hepatocellular Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Aflatoxin-Related Hepatocellular Carcinoma
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-15T11:30:00Z'
description: >-
Aflatoxin-related hepatocellular carcinoma (HCC) is a form of liver cancer strongly
associated with dietary exposure to aflatoxin B1 (AFB1), a mycotoxin produced by
Aspergillus fungi that contaminate stored grains and nuts in tropical regions.
Aflatoxin exposure synergizes dramatically with chronic hepatitis B virus (HBV)
infection, increasing HCC risk approximately 60-fold compared to either factor alone.
The molecular signature of aflatoxin-related HCC is the TP53 R249S mutation, resulting
from AFB1-DNA adduct formation at codon 249. This disease exemplifies gene-environment
interaction in cancer etiology and is most prevalent in sub-Saharan Africa and
Southeast Asia where both aflatoxin exposure and HBV infection are endemic.
categories:
- Hepatic Cancer
- Environmental Cancer
- Solid Tumor
parents:
- hepatocellular carcinoma
infectious_agent:
- name: Hepatitis B Virus (HBV)
infectious_agent_term:
preferred_term: Hepatitis B virus
term:
id: NCBITaxon:10407
label: Hepatitis B virus
description: >-
Chronic HBV infection is a major cofactor in aflatoxin-related HCC, with
synergistic interaction dramatically increasing cancer risk. HBV contributes
through chronic inflammation, hepatocyte regeneration, HBx protein effects,
and viral DNA integration. The combination of HBV and aflatoxin exposure
increases HCC risk approximately 60-fold compared to unexposed individuals.
evidence:
- reference: PMID:14986813
reference_title: Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Chronic hepatitis B virus (HBV) infection and dietary exposure to aflatoxin
B1 (AFB1), two of the major risk factors in the multifactorial aetiology of
hepatocellular carcinoma (HCC), co-exist in those countries with the highest
incidences of and the youngest patients with this tumour
explanation: >-
Review establishing HBV and aflatoxin as co-existing major risk factors
in high-incidence HCC regions.
environmental:
- name: Aflatoxin B1 Exposure
exposure_term:
preferred_term: exposure to aflatoxin
term:
id: ECTO:0001108
label: exposure to aflatoxin
description: >-
Aflatoxin B1 (AFB1) is produced by Aspergillus flavus and A. parasiticus fungi
that contaminate corn, peanuts, and other crops during storage in warm, humid
conditions. After ingestion, AFB1 is metabolized in the liver to a highly
reactive epoxide that forms DNA adducts, preferentially at the third position
of codon 249 in TP53, causing the characteristic G>T transversion (R249S mutation).
evidence:
- reference: PMID:40863326
reference_title: "Cooperation Between Aflatoxin-Induced p53 Aberrations and Hepatitis B Virus in Hepatocellular Carcinoma."
supports: SUPPORT
snippet: Exposure to aflatoxins, potent mycotoxins produced by Aspergillus fungi contaminating staple foods, and chronic hepatitis B virus (HBV) infection are major etiological factors, especially where they co-exist.
explanation: This abstract identifies aflatoxin exposure as a major etiological factor for HCC, supporting the environmental risk described.
pathophysiology:
- name: Aflatoxin B1 Metabolic Activation
description: >-
AFB1 is absorbed from the gut and transported to the liver where it undergoes
cytochrome P450-mediated oxidation (primarily CYP3A4 and CYP1A2) to form
AFB1-8,9-epoxide, a highly reactive electrophilic metabolite. This
CYP-dependent bioactivation step is the proximal event that converts the
parent mycotoxin into its DNA-reactive form.
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
locations:
- preferred_term: liver
term:
id: UBERON:0002107
label: liver
evidence:
- reference: PMID:8261428
reference_title: Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Lymphoblast microsomes expressing only CYP1A2 activated AFB1 to
AFB1-8,9-epoxide (AFB1-8,9-epoxide trapped as the glutathione, conjugate)
at both 16 microM and 128 microM AFB1 concentrations
explanation: >-
Demonstrates that human cytochromes P450 (CYP1A2 and CYP3A4) bioactivate
AFB1 to the reactive AFB1-8,9-epoxide.
downstream:
- target: AFB1-DNA Adduct Formation
description: The reactive epoxide binds covalently to genomic DNA
- name: AFB1-DNA Adduct Formation
description: >-
The reactive AFB1-8,9-exo-epoxide binds covalently to genomic DNA, forming
pro-mutagenic AFB1-N7-guanine adducts preferentially at guanine residues.
This adduct is the DNA lesion that bridges metabolic activation to the
characteristic TP53 codon 249 transversion.
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
evidence:
- reference: PMID:30304666
reference_title: "Epigenetic alterations caused by aflatoxin b1: a public health risk in the induction of hepatocellular carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
which interacts with DNA to form adducts of AFB1-DNA. These adducts
induce mutation in codon 249, mediated by a transversion of G-T in the
p53 tumor suppressor gene
explanation: >-
Establishes covalent AFB1-DNA adduct formation as the distinct lesion
that directly causes the TP53 codon 249 G>T transversion.
downstream:
- target: TP53 R249S Hotspot Mutation
description: DNA adducts at codon 249 cause the characteristic G>T transversion
- name: TP53 R249S Hotspot Mutation
description: >-
The aflatoxin-DNA adduct forms preferentially at the third position of codon 249
in TP53, causing a G>T transversion that results in arginine-to-serine substitution
(R249S). This mutation is found in approximately 50% of HCCs in high-aflatoxin
regions but is rare in low-exposure areas. The R249S mutation impairs p53 DNA
binding and transcriptional activity, eliminating its tumor suppressor function.
evidence:
- reference: PMID:19376640
reference_title: "The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Hepatocellular Carcinoma (HCC) in high-incidence areas (sub-Saharan Africa,
South-Eastern Asia) often contains a somatic mutation at codon 249 in TP53
(R249S). This mutation is rare in low-incidence areas of Europe and the
United States.
explanation: >-
Review article establishing R249S as a biomarker of aflatoxin exposure and
HCC risk in high-incidence geographic regions.
biological_processes:
- preferred_term: DNA damage response
modifier: DECREASED
term:
id: GO:0006974
label: DNA damage response
downstream:
- target: Loss of Cell Cycle Checkpoint Control
description: p53 inactivation removes G1/S and G2/M checkpoint enforcement
- target: Apoptosis Resistance
description: p53 loss impairs DNA damage-induced apoptosis
- name: HBV-Aflatoxin Synergistic Interaction
description: >-
HBV and aflatoxin interact synergistically through multiple mechanisms:
HBV-induced chronic inflammation increases hepatocyte proliferation, allowing
fixation of aflatoxin-induced mutations; HBx protein inhibits DNA repair;
and viral integration may disrupt tumor suppressor genes. The multiplicative
interaction results in approximately 60-fold increased HCC risk compared to
unexposed individuals.
evidence:
- reference: PMID:14986813
reference_title: Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
With the availability of urinary and serum biomarkers that more accurately
reflect dietary exposure to AFB1 than did the initially used food sampling
and dietary questionnaires, cohort studies of patients with HCC in China
and Taiwan have provided compelling evidence for a multiplicative or
sub-multiplicative interaction between HBV and AFB1 in the genesis of human
HCC.
explanation: >-
Review of cohort studies demonstrating synergistic hepatocarcinogenic
interaction between HBV infection and aflatoxin exposure.
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
downstream:
- target: Loss of Cell Cycle Checkpoint Control
description: Combined p53 mutation and HBx effects disable checkpoints
- name: Loss of Cell Cycle Checkpoint Control
description: >-
TP53 R249S mutation combined with HBx-mediated p53 inhibition and Rb pathway
inactivation results in loss of cell cycle checkpoint control. Cells with
DNA damage continue to proliferate, accumulating additional mutations.
evidence:
- reference: PMID:20538734
reference_title: "Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Using HCC cell lines, we show that p.R249S has lost the capacity to bind
to p53 response elements and to transactivate p53 target genes.
explanation: >-
Demonstrates that the R249S mutant loses transactivation of p53 target
genes including those mediating cell cycle checkpoint enforcement.
biological_processes:
- preferred_term: cell cycle checkpoint signaling
modifier: DECREASED
term:
id: GO:0000075
label: cell cycle checkpoint signaling
downstream:
- target: Uncontrolled Hepatocyte Proliferation
description: Checkpoint loss enables proliferation despite DNA damage
- name: Apoptosis Resistance
description: >-
Loss of functional p53 impairs the intrinsic apoptotic pathway in response
to DNA damage. Combined with HBV-associated survival signals, this allows
accumulation of cells with oncogenic mutations.
biological_processes:
- preferred_term: apoptotic process
modifier: DECREASED
term:
id: GO:0006915
label: apoptotic process
- name: Uncontrolled Hepatocyte Proliferation
description: >-
The combination of impaired checkpoints, apoptosis resistance, chronic
inflammation, and hepatocyte regeneration drives clonal expansion of
transformed cells, eventually leading to HCC development.
evidence:
- reference: PMID:20538734
reference_title: "Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
in a cell line that constitutively expresses both p.R249S and the
hepatitis B virus antigen HBx (PLC/PRF/5), silencing of either p.R249S or
HBx by RNA interference slowed down proliferation
explanation: >-
RNAi experiments show that R249S together with HBx drives hepatocyte
proliferation in HCC cell lines, supporting their role in uncontrolled
proliferation.
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
histopathology:
- name: Hepatocellular Carcinoma
finding_term:
preferred_term: Hepatocellular Carcinoma
term:
id: NCIT:C3099
label: Hepatocellular Carcinoma
frequency: VERY_FREQUENT
description: Hepatocellular carcinoma is the most common primary liver malignancy.
evidence:
- reference: PMID:27785449
reference_title: "Hepatocellular carcinoma: a review."
supports: SUPPORT
snippet: "Hepatocellular carcinoma (HCC) is the most common primary liver malignancy"
explanation: Abstract states that HCC is the most common primary liver malignancy.
phenotypes:
- category: Gastrointestinal
name: Abdominal Pain
frequency: FREQUENT
description: >-
Right upper quadrant pain from hepatic capsule stretching or tumor necrosis.
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
- category: Constitutional
name: Weight Loss
frequency: FREQUENT
description: >-
Unintentional weight loss from cancer cachexia and decreased appetite.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Abdominal
name: Hepatomegaly
frequency: VERY_FREQUENT
diagnostic: true
description: >-
Liver enlargement, often palpable, from tumor mass. May be nodular on examination.
phenotype_term:
preferred_term: Hepatomegaly
term:
id: HP:0002240
label: Hepatomegaly
- category: Constitutional
name: Fatigue
frequency: VERY_FREQUENT
description: >-
Profound fatigue from advanced malignancy and often underlying liver dysfunction.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Hepatic
name: Jaundice
frequency: OCCASIONAL
description: >-
Jaundice may develop from biliary obstruction or hepatic failure in advanced disease.
phenotype_term:
preferred_term: Jaundice
term:
id: HP:0000952
label: Jaundice
- category: Hepatic
name: Ascites
frequency: OCCASIONAL
description: >-
Ascites develops from portal hypertension and hypoalbuminemia in advanced disease.
phenotype_term:
preferred_term: Ascites
term:
id: HP:0001541
label: Ascites
biochemical:
- name: Alpha-Fetoprotein (AFP)
notes: >-
Serum AFP is elevated in 50-70% of HCC cases. Used for screening in high-risk
populations and for monitoring treatment response. Very high levels (>400 ng/mL)
are highly specific for HCC.
- name: Aflatoxin-Albumin Adducts
notes: >-
Aflatoxin-albumin adducts in serum serve as biomarkers of recent aflatoxin
exposure and are used in epidemiologic studies to assess population-level exposure.
- name: Urinary Aflatoxin Metabolites
notes: >-
Urinary aflatoxin-N7-guanine adducts reflect recent aflatoxin exposure and
DNA damage. Used as biomarker in exposure assessment studies.
genetic:
- name: TP53
association: Somatic Mutation (R249S)
notes: >-
The TP53 R249S mutation is the molecular signature of aflatoxin-related HCC,
found in approximately 50% of HCCs in high-exposure regions but <5% in
low-exposure areas. Results from AFB1-epoxide adduct formation at the third
position of codon 249 causing G>T transversion. This mutation inactivates
p53 tumor suppressor function.
- name: CTNNB1
association: Somatic Mutation
notes: >-
CTNNB1 (beta-catenin) activating mutations occur in approximately 20-30%
of HCCs and activate Wnt signaling, promoting proliferation.
- name: TERT Promoter
association: Somatic Mutation
notes: >-
TERT promoter mutations occur in approximately 50% of HCCs, activating
telomerase and enabling immortalization. Often an early event in hepatocarcinogenesis.
treatments:
- name: Surgical Resection
description: >-
Hepatic resection is potentially curative for early-stage HCC with preserved
liver function. Limited by underlying cirrhosis and multifocal disease in
many aflatoxin-exposed populations.
evidence:
- reference: PMID:27785449
reference_title: "Hepatocellular carcinoma: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
only orthotopic liver transplantation (OLT) or surgical resection is
curative
explanation: >-
Clinical review confirms that surgical resection is one of the few
curative options for hepatocellular carcinoma.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Liver Transplantation
description: >-
Curative option for early HCC within Milan criteria (single tumor <=5cm or
up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease.
Limited by organ availability.
evidence:
- reference: PMID:27785449
reference_title: "Hepatocellular carcinoma: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
OLT is available for patients who meet or are downstaged into the Milan
or University of San Francisco criteria
explanation: >-
Clinical review describes orthotopic liver transplantation eligibility
under Milan/UCSF criteria, consistent with this treatment option.
treatment_term:
preferred_term: organ transplantation
term:
id: MAXO:0010039
label: organ transplantation
- name: Locoregional Therapy
description: >-
Transarterial chemoembolization (TACE), radiofrequency ablation, or
microwave ablation for unresectable tumors. Provides local control but
not curative for advanced disease.
evidence:
- reference: PMID:27785449
reference_title: "Hepatocellular carcinoma: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Additional treatment modalities include transarterial chemoembolization,
radiofrequency ablation, microwave ablation, percutaneous ethanol
injection, cryoablation
explanation: >-
Review explicitly lists TACE, radiofrequency ablation, and microwave
ablation as locoregional treatments for HCC.
treatment_term:
preferred_term: locoregional interventional procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Systemic Therapy
description: >-
Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC.
Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as
second-line therapy.
evidence:
- reference: PMID:18650514
reference_title: Sorafenib in advanced hepatocellular carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Median overall survival was 10.7 months in the sorafenib group and 7.9
months in the placebo group (hazard ratio in the sorafenib group, 0.69;
95% confidence interval, 0.55 to 0.87; P<0.001).
explanation: >-
SHARP trial demonstrating sorafenib extends median survival by nearly 3
months in advanced hepatocellular carcinoma.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: sorafenib
term:
id: CHEBI:50924
label: sorafenib
- name: Aflatoxin Exposure Prevention
description: >-
Public health interventions including proper grain storage, crop rotation,
and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically
reduces HCC incidence by eliminating the synergistic interaction.
evidence:
- reference: PMID:27785449
reference_title: "Hepatocellular carcinoma: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
HCC can be prevented if there are appropriate measures taken, including
hepatitis B virus vaccination
explanation: >-
Clinical review confirms HBV vaccination as a key preventive measure
reducing HCC incidence in aflatoxin-endemic populations.
treatment_term:
preferred_term: vaccination
term:
id: MAXO:0001017
label: vaccination
disease_term:
preferred_term: hepatocellular carcinoma
term:
id: MONDO:0007256
label: hepatocellular carcinoma
classifications:
icdo_morphology:
classification_value: Carcinoma
harrisons_chapter:
- classification_value: cancer
- classification_value: solid tumor
references:
- reference: DOI:10.1016/j.canlet.2009.02.057
title: 'The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy'
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: 'The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy'
supporting_text: 'The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy'
- reference: DOI:10.1016/j.ejca.2012.02.009
title: 'Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis'
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: 'Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis'
supporting_text: 'Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis'
- reference: DOI:10.1016/j.jhep.2010.04.032
title: Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China
supporting_text: Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China
- reference: DOI:10.1158/1055-9965.epi-05-0612
title: Quantitative Analysis of Plasma TP53 249Ser-Mutated DNA by Electrospray Ionization Mass Spectrometry
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: A mutation in codon 249 of the TP53 gene (249Ser), related to aflatoxin B1 exposure, has previously been associated with hepatocellular carcinoma risk.
supporting_text: A mutation in codon 249 of the TP53 gene (249Ser), related to aflatoxin B1 exposure, has previously been associated with hepatocellular carcinoma risk.
- reference: DOI:10.1158/1055-9965.epi-08-1102
title: <i>TP53 R249S</i> Mutations, Exposure to Aflatoxin, and Occurrence of Hepatocellular Carcinoma in a Cohort of Chronic Hepatitis B Virus Carriers from Qidong, China
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC) has a high mortality in East Asia and Sub-Saharan Africa, two regions where the main etiologic factors are chronic infections with hepatitis B virus and dietary exposure to aflatoxin.
supporting_text: Hepatocellular carcinoma (HCC) has a high mortality in East Asia and Sub-Saharan Africa, two regions where the main etiologic factors are chronic infections with hepatitis B virus and dietary exposure to aflatoxin.
- reference: DOI:10.1289/ehp.1103539
title: Seasonal Variation in <i>TP53 R249S</i> -Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: Seasonal Variation in <i>TP53 R249S</i> -Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection
supporting_text: Seasonal Variation in <i>TP53 R249S</i> -Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection
- reference: DOI:10.1371/journal.pone.0037707
title: 'Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis'
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: 'Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis'
supporting_text: 'Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis'
- reference: DOI:10.3390/toxins16110496
title: '65 Years onโAflatoxin Biomarkers Blossoming: Whither Next?'
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: Aflatoxins are mycotoxins produced by Aspergillus flavus and several other related organisms and are common contaminants of numerous grains and nuts, especially maize (corn) and peanuts.
supporting_text: Aflatoxins are mycotoxins produced by Aspergillus flavus and several other related organisms and are common contaminants of numerous grains and nuts, especially maize (corn) and peanuts.
- reference: DOI:10.3390/toxins17020079
title: 'Fifty Years of Aflatoxin Research in Qidong, China: A Celebration of Team Science to Improve Public Health'
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: The Qidong Liver Cancer Institute (QDLCI) and the Qidong Cancer Registry were established in 1972 with input from doctors, other medical practitioners, and non-medical investigators arriving from urban centers such as Shanghai and Nanjing.
supporting_text: The Qidong Liver Cancer Institute (QDLCI) and the Qidong Cancer Registry were established in 1972 with input from doctors, other medical practitioners, and non-medical investigators arriving from urban centers such as Shanghai and Nanjing.
- reference: DOI:10.3390/toxins18020061
title: 'Aflatoxin and Liver Cancer in China: The Evolving Research Landscape'
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: Aflatoxins, particularly aflatoxin B1 (AFB1), are among the most potent naturally occurring carcinogens and remain a major food-borne hazard in parts of Asia and Africa.
supporting_text: Aflatoxins, particularly aflatoxin B1 (AFB1), are among the most potent naturally occurring carcinogens and remain a major food-borne hazard in parts of Asia and Africa.
- reference: DOI:10.3390/toxins18020090
title: 'Aflatoxins and Human Health: Global Exposure, Disease Burden, and One Health Strategies'
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings:
- statement: Mycotoxin contamination represents a major public health and economic burden worldwide.
supporting_text: Mycotoxin contamination represents a major public health and economic burden worldwide.
- reference: PMID:11185536
title: Epidemiology of hepatocellular carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2000 Sep;14(8):703-9. doi: 10.1155/2000/371801.'
supporting_text: '2000 Sep;14(8):703-9. doi: 10.1155/2000/371801.'
- reference: PMID:11470760
title: 'Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2001 Aug;22(8):1289-94. doi: 10.1093/carcin/22.8.1289.'
supporting_text: '2001 Aug;22(8):1289-94. doi: 10.1093/carcin/22.8.1289.'
- reference: PMID:11525595
title: Associations of plasma aflatoxin B1-albumin adduct level with plasma selenium level and genetic polymorphisms of glutathione S-transferase M1 and T1.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2000;38(2):179-85. doi: 10.1207/S15327914NC382_6.'
supporting_text: '2000;38(2):179-85. doi: 10.1207/S15327914NC382_6.'
- reference: PMID:11783914
title: 'Hepatocellular carcinoma: an update.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2001 Nov-Dec;25(6):497-516. doi: 10.1080/019131201753343539.'
supporting_text: '2001 Nov-Dec;25(6):497-516. doi: 10.1080/019131201753343539.'
- reference: PMID:12534775
title: 'The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2002 Dec;17 Suppl:S441-8. doi: 10.1046/j.1440-1746.17.s4.7.x.'
supporting_text: '2002 Dec;17 Suppl:S441-8. doi: 10.1046/j.1440-1746.17.s4.7.x.'
- reference: PMID:15508099
title: Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2004 Nov;127(5 Suppl 1):S310-8. doi: 10.1053/j.gastro.2004.09.046.'
supporting_text: '2004 Nov;127(5 Suppl 1):S310-8. doi: 10.1053/j.gastro.2004.09.046.'
- reference: PMID:15734960
title: Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2005 Feb;14(2):373-9. doi: 10.1158/1055-9965.EPI-04-0161.'
supporting_text: '2005 Feb;14(2):373-9. doi: 10.1158/1055-9965.EPI-04-0161.'
- reference: PMID:16536303
title: '[Study on the detoxication gene gstM1-gstT1-null and susceptibility to aflatoxin B1 related hepatocellular carcinoma in Guangxi].'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: 2005 Oct;26(10):777-81. [Study on the detoxication gene gstM1-gstT1-null and susceptibility to aflatoxin B1 related hepatocellular carcinoma in Guangxi]. [Article in Chinese] Long XD(1), Ma Y, Wei YP, Deng ZL.
supporting_text: 2005 Oct;26(10):777-81. [Study on the detoxication gene gstM1-gstT1-null and susceptibility to aflatoxin B1 related hepatocellular carcinoma in Guangxi]. [Article in Chinese] Long XD(1), Ma Y, Wei YP, Deng ZL.
- reference: PMID:16799619
title: Genetics of hepatocellular tumors.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2006 Jun 26;25(27):3778-86. doi: 10.1038/sj.onc.1209547.'
supporting_text: '2006 Jun 26;25(27):3778-86. doi: 10.1038/sj.onc.1209547.'
- reference: PMID:16884947
title: The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2006 Sep;36(1):48-55. doi: 10.1016/j.hepres.2006.06.004.'
supporting_text: '2006 Sep;36(1):48-55. doi: 10.1016/j.hepres.2006.06.004.'
- reference: PMID:19345001
title: 'A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2009 Dec 1;286(1):22-8. doi: 10.1016/j.canlet.2009.02.053.'
supporting_text: '2009 Dec 1;286(1):22-8. doi: 10.1016/j.canlet.2009.02.053.'
- reference: PMID:20172840
title: 'Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Hepatocellular carcinoma (HCC), or liver cancer, is the third leading cause of cancer deaths worldwide, with prevalence 16-32 times higher in developing countries than in developed countries.
supporting_text: Hepatocellular carcinoma (HCC), or liver cancer, is the third leading cause of cancer deaths worldwide, with prevalence 16-32 times higher in developing countries than in developed countries.
- reference: PMID:20538734
title: 'Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2010 Aug;31(8):1475-82. doi: 10.1093/carcin/bgq118.'
supporting_text: '2010 Aug;31(8):1475-82. doi: 10.1093/carcin/bgq118.'
- reference: PMID:20547305
title: The changing pattern of epidemiology in hepatocellular carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2010 Jul;42 Suppl 3(Suppl 3):S206-14. doi: 10.1016/S1590-8658(10)60507-5.'
supporting_text: '2010 Jul;42 Suppl 3(Suppl 3):S206-14. doi: 10.1016/S1590-8658(10)60507-5.'
- reference: PMID:24299315
title: Transcriptome profiling of malignant transformed rat hepatic stem-like cells by aflatoxin B1.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2014;61(2):193-204. doi: 10.4149/neo_2014_025.'
supporting_text: '2014;61(2):193-204. doi: 10.4149/neo_2014_025.'
- reference: PMID:2430432
title: Epidemiology and early diagnosis of primary liver cancer in China.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Epidemiological studies in different areas in China have revealed several outstanding risk factors of PLC, i.e., HBV infection, pollution of drinking water, contamination of food by AFB1 and/or nitrosamines, and family predisposition.
supporting_text: Epidemiological studies in different areas in China have revealed several outstanding risk factors of PLC, i.e., HBV infection, pollution of drinking water, contamination of food by AFB1 and/or nitrosamines, and family predisposition.
- reference: PMID:24399650
title: Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2014 May;35(5):4007-15. doi: 10.1007/s13277-013-1524-2.'
supporting_text: '2014 May;35(5):4007-15. doi: 10.1007/s13277-013-1524-2.'
- reference: PMID:24736102
title: Mutation spectrum of hepatocellular carcinoma from eastern-European patients betrays the impact of a complex exposome.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2015 May;25(3):256-63. doi: 10.1038/jes.2014.16.'
supporting_text: '2015 May;25(3):256-63. doi: 10.1038/jes.2014.16.'
- reference: PMID:25421688
title: Detection of epigenetic aberrations in the development of hepatocellular carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2015;1238:709-31. doi: 10.1007/978-1-4939-1804-1_37.'
supporting_text: '2015;1238:709-31. doi: 10.1007/978-1-4939-1804-1_37.'
- reference: PMID:25921147
title: Purple rice bran extract attenuates the aflatoxin B1-induced initiation stage of hepatocarcinogenesis by alteration of xenobiotic metabolizing enzymes.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2015;16(8):3371-6. doi: 10.7314/apjcp.2015.16.8.3371.'
supporting_text: '2015;16(8):3371-6. doi: 10.7314/apjcp.2015.16.8.3371.'
- reference: PMID:25987009
title: Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2015;16(9):3595-604. doi: 10.7314/apjcp.2015.16.9.3595.'
supporting_text: '2015;16(9):3595-604. doi: 10.7314/apjcp.2015.16.9.3595.'
- reference: PMID:26035378
title: Molecular characterization of hepatocarcinogenesis using mouse models.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2015 Jul 1;8(7):743-53. doi: 10.1242/dmm.017624.'
supporting_text: '2015 Jul 1;8(7):743-53. doi: 10.1242/dmm.017624.'
- reference: PMID:27430420
title: Sequential dietary exposure to aflatoxin B1 and fumonisin B1 in F344 rats increases liver preneoplastic changes indicative of a synergistic interaction.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2016 Sep;95:188-95. doi: 10.1016/j.fct.2016.07.017.'
supporting_text: '2016 Sep;95:188-95. doi: 10.1016/j.fct.2016.07.017.'
- reference: PMID:27508181
title: 'Hepatocellular carcinoma: epidemiology and risk factors.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2014 Aug 13;1:115-25. doi: 10.2147/JHC.S44381. eCollection 2014.'
supporting_text: '2014 Aug 13;1:115-25. doi: 10.2147/JHC.S44381. eCollection 2014.'
- reference: PMID:28114823
title: Comparison of urinary aflatoxin M1 and aflatoxin albumin adducts as biomarkers for assessing aflatoxin exposure in Tanzanian children.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2018 Mar;23(2):131-136. doi: 10.1080/1354750X.2017.1285960.'
supporting_text: '2018 Mar;23(2):131-136. doi: 10.1080/1354750X.2017.1285960.'
- reference: PMID:28973694
title: "Editor's Highlight: Pregnancy Alters Aflatoxin B1 Metabolism and Increases DNA Damage in Mouse Liver."
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2017 Nov 1;160(1):173-179. doi: 10.1093/toxsci/kfx171.'
supporting_text: '2017 Nov 1;160(1):173-179. doi: 10.1093/toxsci/kfx171.'
- reference: PMID:29225033
title: Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2017 Dec 21;68(6):1134-1146.e6. doi: 10.1016/j.molcel.2017.11.006.'
supporting_text: '2017 Dec 21;68(6):1134-1146.e6. doi: 10.1016/j.molcel.2017.11.006.'
- reference: PMID:29749584
title: Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2018 Aug;18(3):421-431. doi: 10.1007/s10238-018-0502-9.'
supporting_text: '2018 Aug;18(3):421-431. doi: 10.1007/s10238-018-0502-9.'
- reference: PMID:30045675
title: Exome Sequencing of Fresh-frozen or Formalin-fixed Paraffin-embedded B6C3F1/N Mouse Hepatocellular Carcinomas Arising Either Spontaneously or due to Chronic Chemical Exposure.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2018 Aug;46(6):706-718. doi: 10.1177/0192623318789398.'
supporting_text: '2018 Aug;46(6):706-718. doi: 10.1177/0192623318789398.'
- reference: PMID:30304666
title: 'Epigenetic alterations caused by aflatoxin b1: a public health risk in the induction of hepatocellular carcinoma.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2019 Feb;204:51-71. doi: 10.1016/j.trsl.2018.09.001.'
supporting_text: '2019 Feb;204:51-71. doi: 10.1016/j.trsl.2018.09.001.'
- reference: PMID:31747859
title: Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2020;21(3):269-277. doi: 10.1080/15384047.2019.1685289.'
supporting_text: '2020;21(3):269-277. doi: 10.1080/15384047.2019.1685289.'
- reference: PMID:33457005
title: Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Exposure to dietary aflatoxin B1 (AFB1) induces DNA damage and mutation in the TP53 gene at codon 249, known as the TP53 R249S mutation, and is a major risk factor for hepatocellular carcinoma (HCC).
supporting_text: Exposure to dietary aflatoxin B1 (AFB1) induces DNA damage and mutation in the TP53 gene at codon 249, known as the TP53 R249S mutation, and is a major risk factor for hepatocellular carcinoma (HCC).
- reference: PMID:35438902
title: Aflatoxin levels and prevalence of TP53 aflatoxin-mutations in hepatocellular carcinomas in Mexico.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2022 Feb 25;64(1):35-40. doi: 10.21149/13189.'
supporting_text: '2022 Feb 25;64(1):35-40. doi: 10.21149/13189.'
- reference: PMID:35470382
title: Aflatoxin M1 in milk does not contribute substantially to global liver cancer incidence.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: For 60 y, it has been known that aflatoxin B1 (AFB1), a mycotoxin produced by Aspergillus fungi in certain food and feed crops, causes hepatocellular carcinoma (liver cancer; HCC) in humans.
supporting_text: For 60 y, it has been known that aflatoxin B1 (AFB1), a mycotoxin produced by Aspergillus fungi in certain food and feed crops, causes hepatocellular carcinoma (liver cancer; HCC) in humans.
- reference: PMID:36851773
title: Genetic Susceptibility to Hepatocellular Carcinoma in Patients with Chronic Hepatitis Virus Infection.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2023 Feb 17;15(2):559. doi: 10.3390/v15020559.'
supporting_text: '2023 Feb 17;15(2):559. doi: 10.3390/v15020559.'
- reference: PMID:37589044
title: The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2023 Sep;23(2):262-271. doi: 10.17998/jlc.2023.07.17.'
supporting_text: '2023 Sep;23(2):262-271. doi: 10.17998/jlc.2023.07.17.'
- reference: PMID:37774068
title: Low Frequency of Aflatoxin Induced TP53 Gene Codon 249 Mutation in Hepatocellular Carcinoma from Egyptian Patients Living in the Nile Delta Region.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2023 Sep 1;24(9):3165-3168. doi: 10.31557/APJCP.2023.24.9.3165.'
supporting_text: '2023 Sep 1;24(9):3165-3168. doi: 10.31557/APJCP.2023.24.9.3165.'
- reference: PMID:38751554
title: 'Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Atezolizumab + bevacizumab represent the current standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC).
supporting_text: Atezolizumab + bevacizumab represent the current standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC).
- reference: PMID:38927059
title: Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments-An Overview.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2024 Jun 4;14(6):656. doi: 10.3390/biom14060656.'
supporting_text: '2024 Jun 4;14(6):656. doi: 10.3390/biom14060656.'
- reference: PMID:39824452
title: AFB1 consolidates HBV harm to induce liver injury and carcinogenic risk by inactivating FTCD-AS1-PXR-MASP1 axis.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2025 Feb;511:154057. doi: 10.1016/j.tox.2025.154057.'
supporting_text: '2025 Feb;511:154057. doi: 10.1016/j.tox.2025.154057.'
- reference: PMID:40082982
title: A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2025 Mar 13;23(1):83. doi: 10.1186/s12957-025-03742-0.'
supporting_text: '2025 Mar 13;23(1):83. doi: 10.1186/s12957-025-03742-0.'
- reference: PMID:40250564
title: 'Impact of Probiotic Lacticaseibacillus paracasei Strain Shirota (LcS) on Aflatoxin Exposure among Healthy Malaysian Adults: A Randomized, Double-Blind, Placebo-Controlled Intervention Study.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Limited evidence suggests that probiotic Lacticaseibacillus paracasei strain Shirota (LcS) may reduce aflatoxin exposure in Malaysians, though individual factors influencing aflatoxin exposure remain unclear.
supporting_text: Limited evidence suggests that probiotic Lacticaseibacillus paracasei strain Shirota (LcS) may reduce aflatoxin exposure in Malaysians, though individual factors influencing aflatoxin exposure remain unclear.
- reference: PMID:40344782
title: HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2025 Jun 15;298:118254. doi: 10.1016/j.ecoenv.2025.118254.'
supporting_text: '2025 Jun 15;298:118254. doi: 10.1016/j.ecoenv.2025.118254.'
- reference: PMID:40711142
title: 'Toxicity, Mitigation, and Chemical Analysis of Aflatoxins and Other Toxic Metabolites Produced by Aspergillus: A Comprehensive Review.'
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: '2025 Jun 30;17(7):331. doi: 10.3390/toxins17070331.'
supporting_text: '2025 Jun 30;17(7):331. doi: 10.3390/toxins17070331.'
- reference: PMID:40789982
title: Aflatoxin B1 Promotes M2-like Macrophage Polarization via IL-6 Expression in Hepatocellular Carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: The development of liver cancer in China is mainly caused by HBV, HCV infection, and exposure to aflatoxin.
supporting_text: The development of liver cancer in China is mainly caused by HBV, HCV infection, and exposure to aflatoxin.
- reference: PMID:41201177
title: Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related deaths worldwide.
supporting_text: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related deaths worldwide.
- reference: PMID:41585427
title: Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma
supporting_text: Hsieh RC(1)(2)(3)(4)(5)(6), Chen WP(1), Lee JC(7), Lin CH(1)(8), Chang YC(1), Lee CW(7), Chan KM(7), Hung HC(7), Kuo T(9), Lin SY(10), Chen TC(11), Wu TJ(7), Su CW(9), Chou HS(7), Cheng CH(7), Hsieh YC(9), Huang CY(12), Tran KC(1)(2), Welsh J(13), Hsieh JC(12).
- reference: PMID:8261428
title: Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
found_in:
- Aflatoxin_Related_HCC-deep-research-openscientist.md
findings:
- statement: Gallagher EP(1), Wienkers LC, Stapleton PL, Kunze KL, Eaton DL.
supporting_text: Gallagher EP(1), Wienkers LC, Stapleton PL, Kunze KL, Eaton DL.
- reference: DOI:10.3390/jox15040096
title: Cooperation Between Aflatoxin-Induced p53 Aberrations and Hepatitis B Virus in Hepatocellular Carcinoma
found_in:
- Aflatoxin_Related_HCC-deep-research-falcon.md
findings: []
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Aflatoxin-Related Hepatocellular Carcinoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Aflatoxin-related HCC refers to hepatocellular carcinoma in which chronic exposure to aflatoxinsโespecially aflatoxin B1 (AFB1)โhas played a causal role, typically evidenced by validated exposure biomarkers and/or a characteristic tumor mutational fingerprint. AFB1 is metabolically activated in hepatocytes to a reactive epoxide that forms DNA adducts and induces a characteristic GโT transversion hotspot mutation in TP53 codon 249 (R249S; AGGโAGT) that is widely treated as a molecular โfingerprintโ of aflatoxin-driven hepatocarcinogenesis. Co-exposure with chronic HBV infection substantially amplifies risk (often supra-multiplicatively), and aflatoxin mitigation is a demonstrably effective public-health strategy in endemic regions. (chen2026aflatoxinandliver pages 1-2, morenoleon2025cooperationbetweenaflatoxininduced pages 1-2, koshiol2026aflatoxinsandhuman pages 1-2, gouas2009theaflatoxininducedtp53 pages 1-2)
| Topic | Key finding | Supporting source | Year | Journal | URL | Citation |
|---|---|---|---|---|---|---|
| Core disease concept / definition | Aflatoxin-related hepatocellular carcinoma is HCC causally linked to chronic dietary exposure to aflatoxinsโespecially aflatoxin B1 (AFB1), a potent food-borne hepatocarcinogenโwith risk amplified where chronic HBV infection co-occurs. | Chen et al. | 2026 | Toxins | https://doi.org/10.3390/toxins18020061 | (chen2026aflatoxinandliver pages 1-2) |
| Core disease concept / definition | Aflatoxins are described as โwell-establishedโ liver carcinogens; mechanisms include mutagenic DNA adducts, oxidative stress, mitochondrial dysfunction, immune effects, and epigenetic change. | Koshiol et al. | 2026 | Toxins | https://doi.org/10.3390/toxins18020090 | (koshiol2026aflatoxinsandhuman pages 1-2) |
| Key causal factors / molecular fingerprint | AFB1 is bioactivated in liver to the 8,9-exo-epoxide, generating AFB1-N7-Gua and FAPY adducts that drive G>T transversions; the hallmark hotspot is TP53 codon 249 AGGโAGT (R249S), regarded as a molecular fingerprint of aflatoxin exposure. | Moreno-Leรณn & Aguayo | 2025 | Journal of Xenobiotics | https://doi.org/10.3390/jox15040096 | (morenoleon2025cooperationbetweenaflatoxininduced pages 1-2, morenoleon2025cooperationbetweenaflatoxininduced pages 2-4) |
| Key causal factors / HBV synergy | HBV and aflatoxin interact synergistically in hepatocarcinogenesis; HBx functionally suppresses p53 while AFB1 induces TP53 R249S, converging on p53 pathway disruption. | Moreno-Leรณn & Aguayo | 2025 | Journal of Xenobiotics | https://doi.org/10.3390/jox15040096 | (morenoleon2025cooperationbetweenaflatoxininduced pages 1-2) |
| Key causal factors / tumor frequency | In a Qidong HBV-carrier cohort, TP53 R249S was present in 11/18 available HCC tumors (61%), supporting its strong association with aflatoxin-linked HCC in endemic settings. | Szymaลska et al. | 2009 | Cancer Epidemiology, Biomarkers & Prevention | https://doi.org/10.1158/1055-9965.EPI-08-1102 | (szymanska2009tp53r249smutations pages 1-2, szymanska2009tp53r249smutations pages 4-5) |
| Exposure biomarker | Urinary AFB1โN7โguanine is a validated biomarker of internal dose and was used in Chinese biomonitoring/prospective studies linking baseline exposure to later HCC risk. | Chen et al. | 2026 | Toxins | https://doi.org/10.3390/toxins18020061 | (chen2026aflatoxinandliver pages 2-4, chen2026aflatoxinandliver pages 1-2) |
| Exposure biomarker | AFM1 is listed among validated urinary biomarkers used in population biomonitoring for aflatoxin exposure. | Chen et al. | 2026 | Toxins | https://doi.org/10.3390/toxins18020061 | (chen2026aflatoxinandliver pages 2-4, chen2026aflatoxinandliver media 0564ad30) |
| Exposure biomarker | Serum AFB1โlysine albumin adducts are established long-term exposure biomarkers; Guangxi case-control data used high serum AFB1-lysine levels jointly with HBV mutations to stratify elevated HCC risk. | Xu et al. | 2010 | Journal of Hepatology | https://doi.org/10.1016/j.jhep.2010.04.032 | (xu2010geneticvariationsof pages 1-2) |
| Early-detection biomarker | Circulating TP53 R249S-mutated cfDNA can be detected in plasma/serum before overt cancer and in asymptomatic HBV carriers, supporting early molecular detection in endemic regions. | Villar et al.; Lleonart et al. | 2011; 2005 | Environmental Health Perspectives; Cancer Epidemiology, Biomarkers & Prevention | https://doi.org/10.1289/ehp.1103539 ; https://doi.org/10.1158/1055-9965.EPI-05-0612 | (lleonart2005quantitativeanalysisof pages 1-2, villar2012aflatoxininducedtp53r249s pages 1-2) |
| Early-detection biomarker / quantitative detail | In The Gambia, plasma TP53 249Ser-mutated DNA was quantified in 89 HCC cases, 42 cirrhosis cases, and 131 controls; HCC cases had the highest median level (2,800 copies/mL), and >10,000 copies/mL strongly associated with HCC. | Lleonart et al. | 2005 | Cancer Epidemiology, Biomarkers & Prevention | https://doi.org/10.1158/1055-9965.EPI-05-0612 | (lleonart2005quantitativeanalysisof pages 1-2) |
| Early-detection biomarker / seasonal interaction | In Gambian asymptomatic subjects, R249S positivity was significantly higher in HBsAg-positive individuals surveyed during high-exposure months (61% vs 32%; OR 3.59, 95% CI 2.05โ6.30), indicating temporal interaction among aflatoxin exposure, HBV, and TP53 mutation formation/persistence. | Villar et al. | 2011 | Environmental Health Perspectives | https://doi.org/10.1289/ehp.1103539 | (szymanska2009tp53r249smutations pages 1-2) |
| Quantitative burden metric | A systematic review/meta-analysis estimated the population attributable risk (PAR) of aflatoxin-related HCC at 17% overall (14โ19%). | Liu et al. | 2012 | European Journal of Cancer | https://doi.org/10.1016/j.ejca.2012.02.009 | (liu2012populationattributablerisk pages 1-3) |
| Quantitative burden metric / HBV stratification | The same meta-analysis estimated higher PAR in HBV-positive populations (21%) than HBV-negative populations (8.8%), quantifying the aflatoxinโHBV interaction at the population level. | Liu et al. | 2012 | European Journal of Cancer | https://doi.org/10.1016/j.ejca.2012.02.009 | (liu2012populationattributablerisk pages 1-3) |
| Real-world prevention relevance | Long-term exposure reduction through dietary shift (maize to rice), food governance, and chemopreventive interception (e.g., oltipraz, chlorophyllin, broccoli sprout beverages) was associated with major biomarker declines and marked reduction in HCC burden in Qidong. | Chen et al.; Chen et al. | 2025; 2026 | Toxins; Toxins | https://doi.org/10.3390/toxins17020079 ; https://doi.org/10.3390/toxins18020061 | (chen2026aflatoxinandliver pages 1-2, chen2026aflatoxinandliver media 0564ad30) |
Table: This table summarizes the core definition, causal mechanism, key biomarkers, and burden estimates for aflatoxin-related hepatocellular carcinoma. It is useful as a compact evidence map linking aflatoxin exposure, HBV synergy, TP53 R249S, biomarker-based detection, and population-level impact.
Aflatoxin-related HCC is hepatocellular carcinoma arising (often on a background of chronic liver disease) in which chronic dietary exposure to aflatoxinsโpotent mycotoxins produced by Aspergillus spp.โis a causal contributor. In high-burden regions, aflatoxin exposure often co-occurs with chronic HBV infection and the combination is a major driver of HCC risk. (chen2026aflatoxinandliver pages 1-2, morenoleon2025cooperationbetweenaflatoxininduced pages 1-2, koshiol2026aflatoxinsandhuman pages 1-2)
The aflatoxinโHCC knowledge base is derived from aggregated evidence: biomarker-enabled human epidemiology, molecular pathology of tumors/circulating DNA, and controlled animal models (rodent, duckling) demonstrating causality and providing mechanistic detail. (chen2026aflatoxinandliver pages 1-2, kensler202465yearsonโaflatoxin pages 2-4)
A Guangxi (China) caseโcontrol study (60 HCC cases, 120 matched controls) measured serum AFB1โlysine adducts and found that HBV basal core promoter mutations increased risk and that joint exposure to HBV mutations and high AFB1โlysine adducts further increased HCC risk (e.g., OR 6.94 for 1762T/1764A plus high AFB1โlysine). (xu2010geneticvariationsof pages 1-2)
In the retrieved corpus, protective factors are primarily exposure reduction and HBV control. Chemopreventive/dietary interception strategies that enhance detoxication pathways reduce biomarker burdens in exposed populations (examples in China include oltipraz, chlorophyllin, and broccoli sprout beverages). (chen2026aflatoxinandliver pages 1-2, chen2026aflatoxinandliver pages 2-4)
The core GxE interaction is between the aflatoxin mutagenic mechanism and host context shaped by HBV infection, which functionally perturbs p53 signaling via HBV X protein (HBx), amplifying the consequences of aflatoxin-induced TP53 mutations. (morenoleon2025cooperationbetweenaflatoxininduced pages 1-2)
A recent review describing aflatoxin health effects notes acute aflatoxicosis symptoms including โjaundice, fever, ascites, pedal edema, and vomiting.โ (direct abstract text) (koshiol2026aflatoxinsandhuman pages 9-11)
Not extractable from the retrieved evidence set (limitation). The current corpus is dominated by exposure biology, molecular fingerprinting, and prevention rather than clinical presentation/imaging guidance.
Given limited clinical-phenotype detail in retrieved sources, suggestions are necessarily high-level: - HPO (tumor/disease): Hepatocellular carcinoma (HP term exists but not cited from retrieved sources), Ascites, Jaundice (supported as aflatoxicosis manifestations in a review). (koshiol2026aflatoxinsandhuman pages 9-11) - LOINC/SNOMED: Not directly supported by retrieved sources.
AFB1 is bioactivated in liver by cytochrome P450 enzymes to AFB1-8,9-exo-epoxide, which forms AFB1โN7-guanine and FAPY adducts. If unrepaired, these lesions yield characteristic GโT transversions, particularly at TP53 codon 249, generating R249S (AGGโAGT)โwidely considered a molecular fingerprint of aflatoxin exposure in HCC. (morenoleon2025cooperationbetweenaflatoxininduced pages 1-2, morenoleon2025cooperationbetweenaflatoxininduced pages 2-4, gouas2009theaflatoxininducedtp53 pages 1-2)
Circulating cell-free DNA carrying TP53 R249S can be quantified in plasma and shows patterns consistent with exposure and disease state: - In Thailand, plasma R249S-mutated DNA was detectable at low concentrations (โฅ67 copies/mL) in 53โ64% of patients with primary liver cancer or chronic liver disease and 19% of controls; at โฅ150 copies/mL it was more frequent in HCC without cirrhosis than with cirrhosis (44% vs 21%). (villar2012aflatoxininducedtp53r249s pages 1-2) - In a Qidong HBV-carrier cohort study, tumor R249S frequency was 61% (11/18 tumors); aflatoxinโalbumin adduct positivity was 67% (168/249), and the authors discuss assay sensitivity differences for detecting low levels of circulating mutant DNA. (szymanska2009tp53r249smutations pages 1-2, szymanska2009tp53r249smutations pages 4-5)
Recent reviews summarize additional mechanisms beyond direct mutagenesis, including oxidative stress, mitochondrial dysfunction, immune effects, and epigenetic changes contributing to carcinogenesis. (koshiol2026aflatoxinsandhuman pages 1-2)
Validated biomarkers for exposure and early detection include urinary AFB1โN7โguanine, urinary AFM1, serum AFB1โlysine albumin adducts, and circulating TP53 R249S mutant DNA. (chen2026aflatoxinandliver media 0564ad30, chen2026aflatoxinandliver pages 15-16)
A systematic review and meta-analysis estimated the population attributable risk (PAR) of aflatoxin-related HCC at 17% (14โ19%) overall, higher in HBV-positive populations (21%) than HBV-negative (8.8%). (liu2012populationattributablerisk pages 1-3)
Reviews highlight wide regional variation: aflatoxinโalbumin/lysine adduct prevalence ranges from 0% in some European studies to up to 100% in parts of Africa and Asia. (koshiol2026aflatoxinsandhuman pages 1-2)
Not available in the retrieved evidence set (limitation).
Aflatoxin-specific survival statistics were not found in the retrieved full text. One 2026 review notes that dual-exposure tumors can have distinct immune microenvironment markers (e.g., PD-L1, microvessel density), which may plausibly influence outcomes and therapy response, but outcome quantification was not provided in the retrieved excerpts. (chen2026aflatoxinandliver pages 15-16)
Not extractable from retrieved sources (limitation). The retrieved corpus is prevention/biomarker-centric rather than guideline-centric for established HCC.
China-focused reviews describe chemoprevention/dietary interception trials using oltipraz, chlorophyllin, and broccoli sprout beverages, with reductions in aflatoxin biomarker burdens, supporting feasibility of biochemical risk reduction. (chen2026aflatoxinandliver pages 1-2, chen2026aflatoxinandliver pages 2-4)
(ontology IDs not provided in sources; suggestions are conceptual) - HBV vaccination / antiviral management (risk elimination) - Food decontamination / exposure reduction - Chemopreventive administration (e.g., oltipraz; chlorophyllin; dietary sulforaphane sources)
A clinical trial record was retrieved titled โEvaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Deltaโ (NCT02461966); the retrieved trial metadata does not provide analyzable results here. (chen2026aflatoxinandliver pages 1-2)
A recent One Health-focused review emphasizes intervention โbeginning at the farm level and continuing through pre-harvest, post-harvest, storage, and the consumer level,โ and highlights developing technologies such as electrochemical biosensors and AI methods for detection/decontamination. (koshiol2026aflatoxinsandhuman pages 1-2)
Interventions described include: - Biocontrol: atoxigenic Aspergillus strains. - Pre-harvest: seed/soil management, irrigation, pest control. - Post-harvest: rapid drying, sorting, hermetic storage, moisture control. (koshiol2026aflatoxinsandhuman pages 14-15)
A China-focused synthesis proposes an integrated โ5+1โ framework (source control; process detoxification; tiered governance; short-course interception; precision follow-up, plus climate-sensitive early warning). This is described visually (table/figure) in the retrieved document. (chen2026aflatoxinandliver media 86dda2b5, chen2026aflatoxinandliver media 6173650a)
In Qidong, a long-term โnatural experimentโ (dietary shift from maize to rice plus strengthened food governance) was associated with large reductions in internal exposure biomarkers and a sustained decline in HCC burden in that endemic region (review synthesis). (chen2026aflatoxinandliver pages 2-4)
Not directly addressed in the retrieved evidence, except that aflatoxin is emphasized as a potent carcinogen across species and is discussed in the context of animal susceptibility (e.g., ducks). (kensler202465yearsonโaflatoxin pages 2-4)
A 2024 review summarizes classic animal data demonstrating extreme potency of AFB1 as a hepatocarcinogen in rats, including reports that 15 ppb AFB1 in diet produced 100% hepatocellular carcinomas in Fischer rats under specific experimental conditions, and provides TD50 comparisons across carcinogens. (kensler202465yearsonโaflatoxin pages 2-4)
A China-focused review describes model systems including rats (with RNA-seq showing perturbation of xenobiotic metabolism/redox and transcript processing) and ducklings showing doseโresponse changes in phase I/II metabolism and cell-cycle/apoptosis prior to tumor development. (chen2026aflatoxinandliver pages 15-16)
A 2024 review (โ65 Years onโAflatoxin Biomarkers Blossomingโ) emphasizes continued innovation in aflatoxin biomarkers and provides quantitative context for exposure-to-dose translation and risk framing, underscoring biomarkers as central tools to probe exposureโdisease relationships. (kensler202465yearsonโaflatoxin pages 2-4)
A 2026 synthesis of Chinaโs evidence base highlights biomarker-enabled surveillance, TP53 R249S and mutational signatures, and a structured โ5+1โ prevention framework suitable for implementation and evaluation. It also notes that ~10% of Chinese HCCs may be classifiable as โAFB1-typeโ by mutational signatures. (chen2026aflatoxinandliver pages 15-16, chen2026aflatoxinandliver media 6173650a)
References
(chen2026aflatoxinandliver pages 1-2): Jian-Guo Chen, Thomas W. Kensler, Gui-Ju Sun, Jian Zhu, Jian-Hua Lu, Da Pan, Yong-Hui Zhang, and John D. Groopman. Aflatoxin and liver cancer in china: the evolving research landscape. Toxins, 18:61, Jan 2026. URL: https://doi.org/10.3390/toxins18020061, doi:10.3390/toxins18020061. This article has 0 citations.
(morenoleon2025cooperationbetweenaflatoxininduced pages 1-2): Carolina Moreno-Leรณn and Francisco Aguayo. Cooperation between aflatoxin-induced p53 aberrations and hepatitis b virus in hepatocellular carcinoma. Journal of Xenobiotics, 15:96, Jun 2025. URL: https://doi.org/10.3390/jox15040096, doi:10.3390/jox15040096. This article has 8 citations.
(koshiol2026aflatoxinsandhuman pages 1-2): Jill Koshiol, Amit Yadav, John D. Groopman, and Usha Dutta. Aflatoxins and human health: global exposure, disease burden, and one health strategies. Toxins, 18:90, Feb 2026. URL: https://doi.org/10.3390/toxins18020090, doi:10.3390/toxins18020090. This article has 0 citations.
(gouas2009theaflatoxininducedtp53 pages 1-2): Doriane Gouas, Hong Shi, and Pierre Hainaut. The aflatoxin-induced tp53 mutation at codon 249 (r249s): biomarker of exposure, early detection and target for therapy. Cancer letters, 286 1:29-37, Dec 2009. URL: https://doi.org/10.1016/j.canlet.2009.02.057, doi:10.1016/j.canlet.2009.02.057. This article has 203 citations and is from a peer-reviewed journal.
(morenoleon2025cooperationbetweenaflatoxininduced pages 2-4): Carolina Moreno-Leรณn and Francisco Aguayo. Cooperation between aflatoxin-induced p53 aberrations and hepatitis b virus in hepatocellular carcinoma. Journal of Xenobiotics, 15:96, Jun 2025. URL: https://doi.org/10.3390/jox15040096, doi:10.3390/jox15040096. This article has 8 citations.
(szymanska2009tp53r249smutations pages 1-2): Katarzyna Szymanฬska, Jian-Guo Chen, Yan Cui, Yun Yun Gong, Paul Craig Turner, Steฬphanie Villar, Christopher Paul Wild, Donald Maxwell Parkin, and Pierre Hainaut. Tp53 r249s mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis b virus carriers from qidong, china. Cancer Epidemiology Biomarkers & Prevention, 18:1638-1643, May 2009. URL: https://doi.org/10.1158/1055-9965.epi-08-1102, doi:10.1158/1055-9965.epi-08-1102. This article has 72 citations and is from a domain leading peer-reviewed journal.
(szymanska2009tp53r249smutations pages 4-5): Katarzyna Szymanฬska, Jian-Guo Chen, Yan Cui, Yun Yun Gong, Paul Craig Turner, Steฬphanie Villar, Christopher Paul Wild, Donald Maxwell Parkin, and Pierre Hainaut. Tp53 r249s mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis b virus carriers from qidong, china. Cancer Epidemiology Biomarkers & Prevention, 18:1638-1643, May 2009. URL: https://doi.org/10.1158/1055-9965.epi-08-1102, doi:10.1158/1055-9965.epi-08-1102. This article has 72 citations and is from a domain leading peer-reviewed journal.
(chen2026aflatoxinandliver pages 2-4): Jian-Guo Chen, Thomas W. Kensler, Gui-Ju Sun, Jian Zhu, Jian-Hua Lu, Da Pan, Yong-Hui Zhang, and John D. Groopman. Aflatoxin and liver cancer in china: the evolving research landscape. Toxins, 18:61, Jan 2026. URL: https://doi.org/10.3390/toxins18020061, doi:10.3390/toxins18020061. This article has 0 citations.
(chen2026aflatoxinandliver media 0564ad30): Jian-Guo Chen, Thomas W. Kensler, Gui-Ju Sun, Jian Zhu, Jian-Hua Lu, Da Pan, Yong-Hui Zhang, and John D. Groopman. Aflatoxin and liver cancer in china: the evolving research landscape. Toxins, 18:61, Jan 2026. URL: https://doi.org/10.3390/toxins18020061, doi:10.3390/toxins18020061. This article has 0 citations.
(xu2010geneticvariationsof pages 1-2): Li Xu, Guoqing Qian, Lili Tang, Jianjia Su, and Jia-Sheng Wang. Genetic variations of hepatitis b virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in southern guangxi, china. Journal of hepatology, 53 4:671-6, Oct 2010. URL: https://doi.org/10.1016/j.jhep.2010.04.032, doi:10.1016/j.jhep.2010.04.032. This article has 47 citations and is from a highest quality peer-reviewed journal.
(lleonart2005quantitativeanalysisof pages 1-2): Matilde E. Lleonart, Gregory D. Kirk, Stephanie Villar, Olufunmilayo A. Lesi, Abhijit Dasgupta, James J. Goedert, Maimuna Mendy, Monica C. Hollstein, Ruggero Montesano, John D. Groopman, Pierre Hainaut, and Marlin D. Friesen. Quantitative analysis of plasma tp53 249ser-mutated dna by electrospray ionization mass spectrometry. Cancer Epidemiology, Biomarkers & Prevention, 14:2956-2962, Dec 2005. URL: https://doi.org/10.1158/1055-9965.epi-05-0612, doi:10.1158/1055-9965.epi-05-0612. This article has 41 citations.
(villar2012aflatoxininducedtp53r249s pages 1-2): Stephanie Villar, Sandra Ortiz-Cuaran, Behnoush Abedi-Ardekani, Doriane Gouas, Andre Nogueira da Costa, Amelie Plymoth, Thiravud Khuhaprema, Anant Kalalak, Suleeporn Sangrajrang, Marlin D. Friesen, John D. Groopman, and Pierre Hainaut. Aflatoxin-induced tp53 r249s mutation in hepatocellular carcinoma in thailand: association with tumors developing in the absence of liver cirrhosis. PLoS ONE, 7:e37707, Jun 2012. URL: https://doi.org/10.1371/journal.pone.0037707, doi:10.1371/journal.pone.0037707. This article has 70 citations and is from a peer-reviewed journal.
(liu2012populationattributablerisk pages 1-3): Yan Liu, Chung-Chou H. Chang, Gary M. Marsh, and Felicia Wu. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. European journal of cancer, 48 14:2125-36, Sep 2012. URL: https://doi.org/10.1016/j.ejca.2012.02.009, doi:10.1016/j.ejca.2012.02.009. This article has 474 citations and is from a domain leading peer-reviewed journal.
(chen2026aflatoxinandliver pages 15-16): Jian-Guo Chen, Thomas W. Kensler, Gui-Ju Sun, Jian Zhu, Jian-Hua Lu, Da Pan, Yong-Hui Zhang, and John D. Groopman. Aflatoxin and liver cancer in china: the evolving research landscape. Toxins, 18:61, Jan 2026. URL: https://doi.org/10.3390/toxins18020061, doi:10.3390/toxins18020061. This article has 0 citations.
(kensler202465yearsonโaflatoxin pages 2-4): Thomas W. Kensler and David L. Eaton. 65 years onโaflatoxin biomarkers blossoming: whither next? Toxins, 16:496, Nov 2024. URL: https://doi.org/10.3390/toxins16110496, doi:10.3390/toxins16110496. This article has 17 citations.
(koshiol2026aflatoxinsandhuman pages 14-15): Jill Koshiol, Amit Yadav, John D. Groopman, and Usha Dutta. Aflatoxins and human health: global exposure, disease burden, and one health strategies. Toxins, 18:90, Feb 2026. URL: https://doi.org/10.3390/toxins18020090, doi:10.3390/toxins18020090. This article has 0 citations.
(koshiol2026aflatoxinsandhuman pages 9-11): Jill Koshiol, Amit Yadav, John D. Groopman, and Usha Dutta. Aflatoxins and human health: global exposure, disease burden, and one health strategies. Toxins, 18:90, Feb 2026. URL: https://doi.org/10.3390/toxins18020090, doi:10.3390/toxins18020090. This article has 0 citations.
(chen2026aflatoxinandliver media 86dda2b5): Jian-Guo Chen, Thomas W. Kensler, Gui-Ju Sun, Jian Zhu, Jian-Hua Lu, Da Pan, Yong-Hui Zhang, and John D. Groopman. Aflatoxin and liver cancer in china: the evolving research landscape. Toxins, 18:61, Jan 2026. URL: https://doi.org/10.3390/toxins18020061, doi:10.3390/toxins18020061. This article has 0 citations.
(chen2026aflatoxinandliver media 6173650a): Jian-Guo Chen, Thomas W. Kensler, Gui-Ju Sun, Jian Zhu, Jian-Hua Lu, Da Pan, Yong-Hui Zhang, and John D. Groopman. Aflatoxin and liver cancer in china: the evolving research landscape. Toxins, 18:61, Jan 2026. URL: https://doi.org/10.3390/toxins18020061, doi:10.3390/toxins18020061. This article has 0 citations.
The TP53 R249S mutation (AGGโAGT, p.Arg249Ser) is the most specific molecular biomarker of AFB1 exposure in hepatocarcinogenesis, functioning as both a diagnostic indicator and a mechanistic driver of disease. This somatic missense mutation results from a GโT transversion caused by AFB1-DNA adducts at the third base of codon 249 in the TP53 tumor suppressor gene.
The mutation's predominance is striking: "a mutation at codon 249 (AGG to AGT, arginine to serine, p.R249S) accounts for 90% of TP53 mutations in AFB(1)-related HCC. This specificity suggests that p.R249S confers a selective advantage during hepatocarcinogenesis" (PMID: 20538734). Its role as a population-level biomarker is firmly established: "Lifelong intoxication with aflatoxin B1 is considered as one of the primary causes of this situation. The role of aflatoxin in HCC from a given population is commonly estimated through the prevalence of R249S mutation of TP53, a hallmark for previous exposure to the mycotoxin" (PMID: 29749584).
Geographic prevalence of the R249S mutation directly correlates with AFB1 exposure levels:
| Region | R249S Prevalence | Population | Reference |
|---|---|---|---|
| Middle Africa | 24.8% of HCC patients vs 5.6% controls (P=2.2E-07) | ddPCR of cell-free DNA | PMID: 29749584 |
| Mexico | 6% of HCC cases | 50 HCC tissue blocks | PMID: 35438902 |
| Romania | Present (individual cases) | 48 consecutive HCC cases | PMID: 24736102 |
| Egypt (Nile Delta) | 1% of HCC cases | 104 HCC cases | PMID: 37774068 |
Critically, R249S does not merely abolish p53 tumor suppressor functionโit confers gain-of-function oncogenic activity. The mechanism involves: "CDK4 interacts with p53-RS in the G1/S phase of the cells, phosphorylates it, and enhances its nuclear localization. This is coupled with binding of a peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) to p53-RS" (PMID: 29225033). This CDK4-PIN1-p53R249S-c-Myc axis drives ribosomal biogenesis and cell proliferation, representing a therapeutically targetable pathway. A genome-wide association study further identified three SNPs (ADAMTS18 rs9930984, rs75218075, rs8022091) associated with R249S mutation susceptibility in HCC patients exposed to AFB1 and HBV (PMID: 33457005).
The interaction between chronic HBV infection and AFB1 exposure produces a more-than-multiplicative increase in HCC risk, representing one of the best-characterized geneโenvironment synergies in cancer epidemiology. "Prospective epidemiological studies have shown a more than multiplicative interaction between HBV and aflatoxins in terms of HCC risk" (PMID: 19345001). The global burden is quantified in the landmark risk assessment: "Of the 550,000-600,000 new HCC cases worldwide each year, about 25,200-155,000 may be attributable to aflatoxin exposure. Most cases occur in sub-Saharan Africa, Southeast Asia, and China where populations suffer from both high HBV prevalence and largely uncontrolled aflatoxin exposure in food" (PMID: 20172840).
At the molecular level, a recently discovered mechanism explains this synergy: "HBV infection increased YTHDF2 expression while suppressing PARP1 both in vitro and in vivo. Additionally, HBV infection exacerbated AFB1-induced DNA damage in both experimental settings" (PMID: 40344782). Through N6-methyladenosine (m6A) RNA modification, HBV upregulates the m6A reader protein YTHDF2, which promotes degradation of PARP1 mRNA. Since PARP1 is a critical DNA repair enzyme (poly(ADP-ribose) polymerase), its suppression directly impairs the cell's ability to repair AFB1-induced DNA adducts, increasing mutation frequency and accelerating carcinogenesis. In GSTT1-null chronic HBsAg carriers, AFB1 exposure conferred an OR of 3.7 (95% CI 1.5โ9.3) for HCC, with a statistically significant interaction (P = 0.03) (PMID: 11470760).
The metabolic activation of AFB1 by hepatic cytochrome P450 enzymes is the critical initiating step in aflatoxin-induced carcinogenesis. CYP1A2 is the primary bioactivating enzyme at physiologically relevant AFB1 concentrations: "Treatment of individual human liver microsomes (HLM) with TAO resulted in an average 20% inhibition of AFB1-8,9-epoxide formation at 16 microM AFB1, whereas incubation of HLM with furafylline at 16 microM AFB1 resulted in an average 72% inhibition of AFB1-8,9-epoxide formation at 16 microM AFB1" (PMID: 8261428). CYP3A4 becomes more significant at higher substrate concentrations (46% inhibition by TAO at 128 ฮผM).
Individual susceptibility is critically modulated by phase II detoxification capacity. In The Gambia, "the GSTM1-null genotype [odds ratio (OR), 2.45; 95% confidence interval (95% CI), 1.21-4.95] and the heterozygote XRCC1-399 AG genotype (OR, 3.18; 95% CI, 1.35-7.51) were significantly associated with HCC" (PMID: 15734960). A meta-analysis of 33 studies confirmed GSTM1-null (OR = 1.31, 95% CI 1.07โ1.61) and GSTT1-null (OR = 1.47, 95% CI 1.25โ1.74) as HCC risk factors (PMID: 24399650). Most dramatically, "individuals featuring all of the putative risk genotypes [GSTM1-null, HYL1*2-YH/HH, and XRCC1-AG/GG]" experienced approximately 15-fold increased HCC risk (OR = 14.7) (PMID: 16884947), demonstrating multiplicative geneโgene interactions in AFB1-related hepatocarcinogenesis.
Randomized clinical trials conducted in Qidong, Chinaโa high-risk area for both HBV and AFB1 exposureโestablished proof-of-principle for pharmaceutical chemoprevention of aflatoxin-related HCC. Two mechanistically distinct agents were tested: oltipraz, a dithiolethione that induces phase 2 detoxification enzymes (particularly glutathione S-transferases), and chlorophyllin, a water-soluble chlorophyll derivative that reduces AFB1 oral bioavailability by forming molecular complexes in the gastrointestinal tract.
"Both chemopreventive agents modulated levels of aflatoxin biomarkers in the study participants in manners consonant with protection. Although pharmacological approaches establish proof of principle and help identify key molecular targets for interventions, food-based approaches that also use these molecular targets may be the most practical for widespread application in high-risk populations" (PMID: 15508099). These findings catalyzed development of practical dietary interventions including broccoli sprout beverages (sulforaphane, a potent Nrf2 activator) and green leafy vegetable supplementation as scalable alternatives for resource-limited settings.
Additionally, probiotic supplementation with Lacticaseibacillus paracasei strain Shirota showed a 23% reduction in urinary AFM1 concentrations in a randomized, double-blind, placebo-controlled trial among Malaysian adults (PMID: 40250564), suggesting gut-based interventions as another avenue for reducing AFB1 absorption.
A recent and important discovery reveals that AFB1 actively shapes the tumor microenvironment to promote immune evasion. "We found that AFB1 indirectly influences M2-like macrophage polarization by upregulating IL-6 expression in tumor cells through the NF-ฮบB signaling pathway" (PMID: 40789982). M2-polarized tumor-associated macrophages suppress anti-tumor CD8+ T cell responses, creating an immunosuppressive milieu that may limit the efficacy of immune checkpoint inhibitor monotherapy.
Critically, this mechanism is therapeutically actionable: "Our results demonstrate that the combination treatment significantly reduces tumor growth, decreases the number of M2-like macrophages, and enhances CD8+ T cell infiltration compared to monotherapy with PD1 antibody alone" (PMID: 40789982). The combination of anti-IL-6 with PD-1 blockade overcomes the AFB1-driven immunosuppression, suggesting that patients with aflatoxin-related HCC may benefit from rational combination immunotherapy strategies rather than checkpoint inhibitor monotherapy.
The pathogenesis of aflatoxin-related HCC involves a well-defined multi-step cascade from dietary exposure to malignant transformation, with synergistic contributions from HBV and genetic susceptibility:
STAGE 1: EXPOSURE AND BIOACTIVATION
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
Dietary AFB1 (contaminated maize, groundnuts, cereals)
โ
โผ
Hepatic Uptake โ Endoplasmic Reticulum
โ
โโโโบ CYP1A2 (primary, 72% at low [AFB1])โโโบ AFB1-exo-8,9-Epoxide (AFBO)
โ โ
โโโโบ CYP3A4 (46% at high [AFB1])โโโโโโโโโโโโโโโโโโโบโโ
โ
โโโโโโโโโโโโโโโโโค
โ โ
โผ โผ
Phase II Detox DNA Adduct Formation
(GSTs: GSTA3) (AFB1-N7-Guanine)
โ โ
โผ โผ
EXCRETION MUTAGENESIS
(safe) GโT transversion
STAGE 2: MUTAGENESIS AND TUMOR SUPPRESSOR LOSS
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
AFB1-N7-Guanine adduct at TP53 codon 249
โ
โผ
TP53 R249S Mutation (AGGโAGT)
โ
โโโโโโโโโโโโโโดโโโโโโโโโโโโโ
โ โ
โผ โผ
LOSS OF FUNCTION GAIN OF FUNCTION
โข No DNA binding โข CDK4 phosphorylation
โข No transcription โข PIN1 binding
โข Failed apoptosis โข c-Myc activation
โข Failed cell cycle โข Ribosomal biogenesis
arrest โข Enhanced proliferation
STAGE 3: HBV SYNERGY (when co-infected)
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
HBV Chronic Infection
โ
โโโโบ HBx protein โโโบ p53-R249S complex โโโบ Enhanced proliferation
โ
โโโโบ YTHDF2 โ โโโบ PARP1 โ (m6A-mediated) โโโบ Impaired DNA repair
โ โโโบ More mutations
โโโโบ Chronic hepatitis โโโบ Regeneration cycles โโโบ Fixation of mutations
STAGE 4: IMMUNE EVASION AND TUMOR PROGRESSION
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
AFB1 exposure (tumor cells)
โ
โผ
NF-ฮบB activation โโโบ IL-6 upregulation
โ
โผ
M2 macrophage polarization
โ
โโโโบ CD8+ T cell suppression
โ
โโโโบ Immunosuppressive microenvironment
โ
โผ
HEPATOCELLULAR CARCINOMA
The balance between bioactivation and detoxification determines individual cancer risk:
| Genotype Combination | Effect | OR (95% CI) | Reference |
|---|---|---|---|
| GSTM1-null alone | Reduced AFB1-epoxide conjugation | 2.45 (1.21โ4.95) | PMID: 15734960 |
| GSTT1-null + AFB1 + HBsAg+ | Impaired detox in HBV carriers | 3.7 (1.5โ9.3) | PMID: 11470760 |
| XRCC1-399 AG | Impaired base excision repair | 3.18 (1.35โ7.51) | PMID: 15734960 |
| Triple risk (GSTM1-null + HYL1*2 + XRCC1) | Multiplicative interaction | ~14.7 | PMID: 16884947 |
| GSTM1+GSTT1 double-null (meta-analysis) | Combined deficiency | 1.88 (1.41โ2.50) | PMID: 24399650 |
The detailed mechanistic understanding of aflatoxin-related HCC suggests multiple therapeutic intervention points:
| Identifier | Code/ID |
|---|---|
| ICD-10 | C22.0 (Hepatocellular carcinoma) |
| ICD-11 | 2C12.0 (Hepatocellular carcinoma) |
| MeSH | D006528 (Carcinoma, Hepatocellular); D016604 (Aflatoxin B1) |
| MONDO | MONDO:0007256 (hepatocellular carcinoma) |
| OMIM | 114550 (Hepatocellular Carcinoma) |
| Orphanet | ORPHA:88673 (Hepatocellular carcinoma) |
| IARC | Group 1 carcinogen (Aflatoxin B1) |
| CHEBI | CHEBI:2504 (Aflatoxin B1) |
Aflatoxin B1 (AFB1; CHEBI:2504) is the most potent naturally occurring hepatocarcinogen, a secondary metabolite of Aspergillus flavus (NCBI Taxon: 5059) and Aspergillus parasiticus (NCBI Taxon: 5067). These fungi contaminate staple crops including maize, groundnuts, tree nuts, and cereals, particularly under warm, humid storage conditions (PMID: 40711142). In southern Mexico, the prevalence of AFB1 in serum samples reaches 85.5% (95% CI 72.1โ93.1) (PMID: 35438902).
Environmental: - Chronic HBV infection: present in ~80% of HCC worldwide (PMID: 11185536) - Fumonisin B1 co-exposure: synergistically increases GST-P+ foci 7โ13-fold in rat models (PMID: 27430420) - Alcohol consumption, smoking, obesity/metabolic syndrome (PMID: 41201177) - Male sex (2โ3:1 male predominance) (PMID: 11185536) - Pregnancy: 2-fold higher AFB1-N7-guanine DNA adducts due to elevated CYP expression (PMID: 28973694)
Genetic susceptibility modifiers: GSTM1-null, GSTT1-null, XRCC1-399 AG, HYL1*2, ADAMTS18 variants (see detailed quantification in Findings above)
| Phenotype | HPO Term | Type | Onset | Severity | Frequency |
|---|---|---|---|---|---|
| Hepatomegaly | HP:0002240 | Physical sign | Adult | Variable | ~60โ70% |
| Right upper quadrant pain | HP:0100280 | Symptom | Adult | Moderateโsevere | ~50โ60% |
| Weight loss | HP:0001824 | Symptom | Adult | Progressive | ~30โ50% |
| Jaundice | HP:0000952 | Clinical sign | Late | Variable | ~20โ40% |
| Ascites | HP:0001541 | Physical sign | Advanced | Severe | ~20โ30% |
| Fatigue | HP:0012378 | Symptom | Variable | Variable | ~30โ50% |
| Portal hypertension | HP:0001409 | Clinical sign | Advanced | Severe | ~40โ60% |
| Elevated AFP | HP:0006254 | Lab abnormality | Variable | Variable | ~60โ70% |
| Elevated transaminases | HP:0002910 | Lab abnormality | Variable | Variable | ~60โ80% |
| Thrombocytopenia | HP:0001873 | Lab abnormality | Cirrhotic stage | Variable | ~30โ50% |
In AFB1-endemic regions, HCC presents at notably younger ages (20sโ40s in sub-Saharan Africa) compared to non-endemic areas (50sโ70s). "In these regions and populations, the tumor shows a distinct shift in age distribution toward the younger ages, seen to greatest extent in sub-Saharan Black Africans" (PMID: 27508181).
| Pathway | Role in Disease | GO/KEGG Terms |
|---|---|---|
| CYP450 bioactivation | AFB1 โ AFBO initiating event | GO:0006805 (xenobiotic metabolic process) |
| p53 tumor suppression | Loss of apoptosis/cell cycle control | GO:0006915 (apoptotic process) |
| CDK4-PIN1-c-Myc | R249S gain-of-function proliferation | GO:0008283 (cell proliferation) |
| NF-ฮบB/IL-6/STAT3 | Inflammation, immune evasion | GO:0038061 (NF-kappaB signaling) |
| Nrf2/Keap1 | Oxidative stress response | GO:0006979 (response to oxidative stress) |
| Wnt/ฮฒ-catenin | Proliferation (less prominent in AFB1-HCC) | hsa04310 (Wnt signaling pathway) |
| MAPK/TGF-ฮฒ | Cell adhesion, migration (AFB1-transformed cells) | GO:0000165 (MAPK cascade) |
| Cell Type | CL Term | Role |
|---|---|---|
| Hepatocyte | CL:0000182 | Primary target of transformation |
| Kupffer cell | CL:0000091 | Inflammatory response, M2 polarization |
| Hepatic stellate cell | CL:0000632 | Fibrosis, tumor microenvironment |
| CD8+ T lymphocyte | CL:0000794 | Anti-tumor immunity (suppressed) |
| Tumor-associated macrophage | CL:0000863 | M2-polarized, immunosuppressive |
| Hepatic progenitor cell | CL:0002196 | Potential cell of origin |
| Test | Purpose | Notes |
|---|---|---|
| Serum AFP | Screening/diagnosis | Elevated in ~60โ70%; AFP-L3 fraction improves specificity |
| DCP (PIVKA-II) | Diagnosis | Complementary to AFP |
| AFB1-albumin adducts | Exposure biomarker | ELISA; reflects 2โ3 months exposure (PMID: 11525595) |
| Urinary AFM1 | Exposure biomarker | Reflects recent exposure (PMID: 28114823) |
| Multiphasic CT/MRI | Imaging diagnosis | Arterial hyperenhancement + washout |
| Ultrasound | Screening | Every 6 months in high-risk populations |
| TP53 R249S (ddPCR) | Molecular diagnosis + exposure | Liquid biopsy in cell-free DNA (PMID: 29749584) |
| COSMIC Signature 24 | Mutational signature | AFB1-associated pattern; C>A mutations (PMID: 30045675) |
| Regimen | Evidence | MAXO Term |
|---|---|---|
| Atezolizumab + Bevacizumab | Standard of care; 88% probability of best 30-month OS (PMID: 38751554) | MAXO:0000451 |
| Durvalumab + Tremelimumab | Approved first-line | MAXO:0000451 |
| Sorafenib | First approved agent (2007) | MAXO:0001052 |
| Lenvatinib | Non-inferior to sorafenib (PMID: 37589044) | MAXO:0001052 |
Co-targeting CDK4 (palbociclib/PD-0332991) + p53-R249S restoration (CP-31398) showed synergistic inhibition of HCC cell growth in a p53-R249S-dependent manner (PMID: 31747859). This represents a precision medicine approach specifically for AFB1-related HCC.
Anti-IL-6 + anti-PD-1 combination overcomes AFB1-driven M2 macrophage polarization, "significantly reduces tumor growth, decreases the number of M2-like macrophages, and enhances CD8+ T cell infiltration" (PMID: 40789982).
| Model | Strengths | Limitations |
|---|---|---|
| F344 rat + AFB1 | Gold standard; GST-P+ foci, HCC development; chemoprevention testing | No HBV infection capability |
| B6C3F1/N mouse + AFB1 | COSMIC Signature 24 matches human HCC (PMID: 30045675) | Species CYP differences |
| HBsAg transgenic mouse + AFB1 | Synergy recapitulation; 11-gene HCC signature (PMID: 26035378) | Mouse HBV biology differs |
| Tree shrew + HBV + AFB1 | Natural HBV susceptibility; FTCD-AS1-PXR-MASP1 axis (PMID: 39824452) | Limited genetic tools |
| Category | Terms |
|---|---|
| MONDO | MONDO:0007256 (hepatocellular carcinoma) |
| HPO | HP:0002240 (Hepatomegaly), HP:0001824 (Weight loss), HP:0000952 (Jaundice), HP:0001541 (Ascites), HP:0001409 (Portal hypertension), HP:0006254 (Elevated AFP), HP:0002910 (Elevated transaminases) |
| GO (BP) | GO:0006805 (Xenobiotic metabolism), GO:0006749 (Glutathione metabolism), GO:0006281 (DNA repair), GO:0006915 (Apoptosis), GO:0008283 (Cell proliferation), GO:0006979 (Oxidative stress response), GO:0006954 (Inflammatory response) |
| GO (CC) | GO:0005634 (Nucleus), GO:0005783 (ER), GO:0005739 (Mitochondria), GO:0005829 (Cytosol) |
| CL | CL:0000182 (Hepatocyte), CL:0000091 (Kupffer cell), CL:0000632 (Hepatic stellate cell), CL:0000794 (CD8+ T cell) |
| UBERON | UBERON:0002107 (Liver), UBERON:0002048 (Lung), UBERON:0002481 (Bone) |
| CHEBI | CHEBI:2504 (Aflatoxin B1), CHEBI:50924 (Sorafenib), CHEBI:16856 (Glutathione) |
| MAXO | MAXO:0000451 (Immunotherapy), MAXO:0000004 (Surgery), MAXO:0001175 (Transplantation), MAXO:0001017 (Vaccination) |
| PMID | Key Contribution | Citation Basis |
|---|---|---|
| 20172840 | Quantified 25,200โ155,000 annual AFB1-attributable HCC cases globally | Direct quote validated from abstract |
| 20538734 | Demonstrated R249S accounts for 90% of TP53 mutations in AFB1-HCC; functional studies | Direct quote validated from abstract |
| 29749584 | ddPCR detection of R249S in cfDNA; 24.8% prevalence in Middle Africa | Direct quote validated from abstract |
| 19345001 | Established more-than-multiplicative HBV-AFB1 synergy | Direct quote validated from abstract |
| 8261428 | Defined CYP1A2 (72%) and CYP3A4 as AFB1 bioactivation enzymes | Direct quote validated from abstract |
| 29225033 | CDK4-PIN1-c-Myc gain-of-function mechanism of p53-R249S | Direct quote validated from abstract |
| 15734960 | GSTM1/XRCC1 polymorphisms and HCC risk in AFB1-endemic Gambia | Direct quote validated from abstract |
| 16884947 | Triple risk genotype (GSTM1+HYL1*2+XRCC1) = 15-fold HCC risk | Direct quote validated from abstract |
| 15508099 | Oltipraz and chlorophyllin clinical trial results | Direct quote validated from abstract |
| 40789982 | AFB1 drives M2 macrophage polarization via IL-6/NF-ฮบB; anti-IL-6+PD-1 therapy | Direct quote validated from abstract |
| 40344782 | HBV-YTHDF2-PARP1 axis in DNA damage exacerbation | Direct quote validated from abstract |
| 33457005 | GWAS identified ADAMTS18 loci for R249S susceptibility | Direct quote validated from abstract |
| 31747859 | CDK4 + p53-R249S co-targeting synergistic therapy | Direct quote validated from abstract |
| 11470760 | GSTT1-null ร AFB1 interaction in HBsAg carriers (OR=3.7) | Direct quote validated from abstract |
| 24399650 | Meta-analysis of GSTM1/GSTT1 and HCC risk (33 studies) | Direct quote validated from abstract |
| PMID | Topic |
|---|---|
| 27508181 | HCC epidemiology and risk factors (comprehensive review) |
| 38927059 | Molecular mechanisms and targeted treatments in HCC |
| 16799619 | Two pathways of hepatocarcinogenesis (chromosomal instability) |
| 25421688 | Epigenetic aberrations in HCC |
| 30304666 | AFB1-induced epigenetic alterations |
| 30045675 | Exome sequencing and COSMIC Signature 24 in mouse HCC |
| 26035378 | HBsAg transgenic mouse + AFB1 model characterization |
| 28973694 | Pregnancy alters AFB1 metabolism and DNA damage |
| 38751554 | Network meta-analysis of first-line HCC therapies |
| 12534775 | AFB1/HBV role and prevention in Guinea-Conakry |
Nosological classification: Aflatoxin-related HCC lacks a distinct MONDO or OMIM entry separate from general HCC, limiting systematic data aggregation and research coordination for this specific etiological subtype.
Dose-response quantification: Precise dose-response relationships for AFB1 alone remain difficult to determine in human populations due to confounding from HBV co-exposure, variable dietary patterns, and lack of long-term prospective exposure monitoring.
R249S therapeutic translation: The CDK4/6 inhibitor + p53-restoring compound combination (PD-0332991 + CP-31398) has been characterized only in cell lines and animal models. No human clinical trials have tested this approach in R249S-positive HCC patients.
Immunotherapy optimization: The IL-6/NF-ฮบB/M2 macrophage axis driving immunosuppression is a very recent discovery (2025โ2026). The clinical relevance of anti-IL-6 + anti-PD-1 combinations specifically for AFB1-related HCC has not been validated in human trials.
Biomarker accessibility: AFB1-albumin adducts, urinary AFM1, and ddPCR-based R249S cfDNA detection are validated research biomarkers but remain unavailable in most clinical settings in the resource-limited regions where disease burden is highest.
Scalability of chemoprevention: While oltipraz and chlorophyllin show proof-of-concept efficacy, large-scale implementation in endemic regions faces logistical, economic, and sustainability challenges. Long-term cancer incidence endpoints have not been evaluated.
Incomplete multi-omics profiling: Comprehensive single-cell transcriptomic, epigenomic, and proteomic profiling specifically comparing AFB1-related vs. non-AFB1-related HCC has not been performed at scale, limiting understanding of subtype-specific biology.
Pharmacogenomics of treatment response: The role of CYP450 and GST polymorphisms in modulating treatment response (beyond disease risk) remains poorly characterized.
Phase II trial of CDK4/6 inhibitor + p53-restoring compound in R249S-positive HCC: Stratify advanced HCC patients by TP53 R249S status (liquid biopsy) and test palbociclib + CP-31398 (or next-generation p53 reactivators) in a biomarker-selected population, with R249S-negative patients as controls.
Randomized trial of anti-IL-6 (tocilizumab) + anti-PD-1 in AFB1-endemic HCC: Evaluate whether targeting the AFB1-driven immunosuppressive microenvironment improves checkpoint inhibitor response rates in sub-Saharan African or Southeast Asian HCC cohorts.
Liquid biopsy validation for population screening: Prospective evaluation of ddPCR-based TP53 R249S detection in cell-free DNA as both a diagnostic and population-level exposure surveillance biomarker in high-risk communities.
Multi-country prospective cohort study: Longitudinal assessment of AFB1 biomarkers (AFB1-albumin adducts, urinary AFM1) combined with genomic characterization (GST, XRCC1, CYP polymorphisms) and HCC incidence outcomes across multiple AFB1-endemic African countries.
Large-scale dietary chemoprevention trial: Evaluate food-based interventions (chlorophyllin, broccoli sprout beverage, probiotics) at population scale in endemic regions with cancer incidence as a primary endpoint, complementing the existing biomarker-based proof-of-concept data.
Single-cell RNA sequencing of R249S-positive vs. wild-type HCC tumors: Characterize tumor microenvironment differences with emphasis on macrophage polarization states, T cell exhaustion markers, and cancer-associated fibroblast subtypes.
CRISPR functional genomics screen: Systematically identify synthetic lethal interactions with TP53 R249S in isogenic hepatocyte models to discover new therapeutic targets beyond the CDK4-PIN1 axis.
Integrated multi-omics analysis (TCGA/ICGC reanalysis): Stratify existing HCC genomic datasets by R249S status and AFB1 exposure biomarkers to define the complete molecular subtype signature of aflatoxin-related HCC.
Rapid AFB1 testing deployment: Develop and field-test lateral-flow immunoassay devices for AFB1 detection in food markets across endemic regions, coupled with community education programs about proper crop storage.
Cost-effectiveness modeling: Comprehensive health-economic analysis of integrated prevention programs (HBV vaccination + aflatoxin reduction + chemoprevention + HCC screening) to guide resource allocation in high-burden countries.
Report generated: 2026-05-05 | Based on analysis of 78 published papers | 5 confirmed findings | 1 research iteration